发明名称 Methods and compositions for reducing amyloid beta levels
摘要 The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and/or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for treating cerebral angiopathy, in an individual, the methods generally involving administering to an individual having AD a therapeutically effective amount of an agent that reduces cystatin C levels and/or activity. The present invention further provides methods for identifying an agent that reduces cystatin C levels and/or activity.
申请公布号 US9347085(B2) 申请公布日期 2016.05.24
申请号 US201414219556 申请日期 2014.03.19
申请人 The J. David Gladstone Institutes 发明人 Gan Li;Mucke Lennart
分类号 G01N33/53;A61K39/00;A61K39/395;C12Q1/37;A61K38/55;C07K16/38;C12N15/113;G01N33/68;A61K31/7052;C12Q1/68;A61K38/00 主分类号 G01N33/53
代理机构 Bozicevic, Field & Francis LLP 代理人 Rubin Michael B.;Bozicevic, Field & Francis LLP
主权项 1. A method of reducing the level of human amyloid beta protein in a cell or a tissue, the method comprising contacting the cell or tissue with an antibody that selectively reduces cystatin C levels and/or activity in the cell or tissue, wherein reduction of cystatin C levels and/or activity results in a reduced level of human amyloid beta protein in the cell or tissue.
地址 San Francisco CA US